Roche's (ROG SW) Pharma Head Graham says we continue to think that the obesity drug market will be over USD 100bln

Roche's (ROG SW) Pharma Head Graham says we continue to think that the obesity drug market will be over USD 100bln.

Roche's Pharma Head indicates a strong outlook for the obesity drug market, projecting it to exceed USD 100 billion. This bullish sentiment could suggest Roche's strategic positioning in a growing segment, potentially driving future investment and M&A activity in pharmaceuticals. The implications extend to competitor evaluations and overall market sentiment in related sectors, influencing equities and potentially impacting currency flows linked to Swiss companies.